WO1999047152A3 - Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells - Google Patents

Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells Download PDF

Info

Publication number
WO1999047152A3
WO1999047152A3 PCT/US1999/005918 US9905918W WO9947152A3 WO 1999047152 A3 WO1999047152 A3 WO 1999047152A3 US 9905918 W US9905918 W US 9905918W WO 9947152 A3 WO9947152 A3 WO 9947152A3
Authority
WO
WIPO (PCT)
Prior art keywords
dipeptidyl peptidase
activating protein
suppressing
subject
fibroblast activating
Prior art date
Application number
PCT/US1999/005918
Other languages
French (fr)
Other versions
WO1999047152A2 (en
Inventor
Alan N Houghton
Umadevi V Wesley
Jedd D Wolchok
Original Assignee
Sloan Kettering Inst Cancer
Alan N Houghton
Umadevi V Wesley
Jedd D Wolchok
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Alan N Houghton, Umadevi V Wesley, Jedd D Wolchok filed Critical Sloan Kettering Inst Cancer
Priority to AU33572/99A priority Critical patent/AU3357299A/en
Publication of WO1999047152A2 publication Critical patent/WO1999047152A2/en
Publication of WO1999047152A3 publication Critical patent/WO1999047152A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides a method of suppressing the malignant phenotype or inducing apoptosis of cancer cells in a subject, comprising introducing into the cancer cell an amount of a nucleic acid encoding a dipeptidyl peptidase IV protein or fibroblast activating protein-α, thereby suppressing the malignant phenotype of the cancer. This invention provides a method of treating a subject with cancer which comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a purified dipeptidyl peptidase IV protein or fibroblast activating protein-α and a pharmaceutical acceptable carrier or diluent. This invention provides a method of inducing expression of dipeptidyl peptidase IV or fibroblast activating protein-α in cancer cells of a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an agent capable of activating transcription of the dipeptidyl peptidase IV gene or fibroblast activating protein-α and a pharmaceutical acceptable carrier or diluent.
PCT/US1999/005918 1998-03-20 1999-03-19 Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells WO1999047152A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33572/99A AU3357299A (en) 1998-03-20 1999-03-19 Use of dipeptidyl peptidase (dpp4) for suppressing the malignant phenotype of cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7880698P 1998-03-20 1998-03-20
US60/078,806 1998-03-20

Publications (2)

Publication Number Publication Date
WO1999047152A2 WO1999047152A2 (en) 1999-09-23
WO1999047152A3 true WO1999047152A3 (en) 2000-01-27

Family

ID=22146339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005918 WO1999047152A2 (en) 1998-03-20 1999-03-19 Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells

Country Status (2)

Country Link
AU (1) AU3357299A (en)
WO (1) WO1999047152A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6709651B2 (en) 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
AU2003302017A1 (en) * 2002-05-17 2004-06-15 Board Of Regents, The University Of Texas System Cd26-based therapies for cancers and immune disease
US7241581B2 (en) * 2002-08-16 2007-07-10 Rigel Pharmaceuticals, Inc. Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
WO2005071073A1 (en) * 2004-01-09 2005-08-04 Point Therapeutics, Inc. Fap compositions and the use thereof for immunomodulation
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
CN100344325C (en) * 2005-10-17 2007-10-24 华南师范大学 Medicine for treating cervical cancer and preparation method and application thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602007013234D1 (en) * 2006-07-19 2011-04-28 Genentech Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2259791A2 (en) * 2008-03-05 2010-12-15 Tel HaShomer Medical Research Infrastructure and Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
EP3555627B1 (en) 2016-12-14 2023-11-22 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BÖHM ET AL: "HUMAN DIPEPTIDYL PEPTIDASE IV GENE PROMOTER: TISSUE-SPECIFIC REGULATION FROM A TATA-LESS GC-RICH SEQUENCE CHARACTERISTIC OF A HOUSEKEEPING GENE PROMOTER", BIOCHEMICAL JOURNAL, vol. 311, 1995, pages 835 - 843, XP002124291 *
MORRISON M E ET AL: "A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.", JOURNAL OF EXPERIMENTAL MEDICINE, (1993 APR 1) 177 (4) 1135-43., XP002124289 *
PINEIRO-SANCHEZ, MAYRA L. ET AL: "Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997) VOL. 272, NO. 12, PP. 7595-7601., XP002124292 *
WESLEY, U. ET AL: "Implicating a cell surface peptidase, adenosine deaminase binding protein (ADAbp) in growth and survival of melanocytes and melanoma.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (1997) VOL. 38, NO. 0, PP. 626. MEETING INFO.: EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH SAN DIEGO, CALIFORNIA, USA APRIL 12-16, 1997, XP002124290 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
WO1999047152A2 (en) 1999-09-23
AU3357299A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
WO1999047152A3 (en) Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells
DE50015518D1 (en) PROCEDURE TO REDUCE ANTIGENITY OF THE ADENO ASSOCIATED VIRUS STRUCTURAL PROTEIN
SI0957941T1 (en) USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE
WO2008088422A3 (en) Toxin peptide therapeutic agents
AU7585498A (en) Inhibition of p38 kinase activity by aryl ureas
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
HU9503035D0 (en) Defective recombinant adenoviruses for gene therapy of tumours
CA2012312A1 (en) Genetic units for inhibiting the function of rna
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
HK1047129A1 (en) Sequence-specific dna recombination in eukaryotic cells
GB9930418D0 (en) Replication incompetent herpes virus vectors
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
GB0100551D0 (en) Protein
DE60036105D1 (en) HERPES-SIMPLEX VIRUS EXPRESSING THE GENE OF INTERLEUKIN-12 AND ITS USE IN THE TREATMENT OF CANCER
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
GB0418388D0 (en) Cell therapy
NZ515989A (en) Equine granulocyte-macrophage colony-stimulating factor (GM-CSF)
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
AU2676801A (en) Xylosyltransferase and isoforms thereof
WO2000062815A3 (en) Novel pharmaceutical composition suitable for gene therapy
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
WO2002042325A3 (en) Cyp1b1 nucleic acids and methods of use
AU2001220255A1 (en) Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferationof cancer cell using the expression vector

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09646541

Country of ref document: US

122 Ep: pct application non-entry in european phase